Literature DB >> 28694296

Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL.

Mikael Larsson1, Christopher M Allan2, Rachel S Jung2, Patrick J Heizer2, Anne P Beigneux2, Stephen G Young3, Loren G Fong4.   

Abstract

apoC-III is often assumed to retard the intravascular processing of triglyceride-rich lipoproteins (TRLs) by inhibiting LPL, but that view is based largely on studies of free LPL. We now recognize that intravascular LPL is neither free nor loosely bound, but instead is tightly bound to glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPIHBP1) on endothelial cells. Here, we revisited the effects of apoC-III on LPL, focusing on apoC-III's capacity to affect the activity of GPIHBP1-bound LPL. We found that TRLs from APOC3 transgenic mice bound normally to GPIHBP1-bound LPL on cultured cells in vitro and to heart capillaries in vivo. However, the triglycerides in apoC-III-enriched TRLs were hydrolyzed more slowly by free LPL, and the inhibitory effect of apoC-III on triglyceride lipolysis was exaggerated when LPL was bound to GPIHBP1 on the surface of agarose beads. Also, recombinant apoC-III reduced triglyceride hydrolysis by free LPL only modestly, but the inhibitory effect was greater when the LPL was bound to GPIHBP1. A mutant apoC-III associated with low plasma triglyceride levels (p.A23T) displayed a reduced capacity to inhibit free and GPIHBP1-bound LPL. Our results show that apoC-III potently inhibits triglyceride hydrolysis when LPL is bound to GPIHBP1.
Copyright © 2017 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1; hypertriglyceridemia; lipoprotein lipase

Mesh:

Substances:

Year:  2017        PMID: 28694296      PMCID: PMC5580902          DOI: 10.1194/jlr.M078220

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  35 in total

1.  Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.

Authors:  Mikael Larsson; Evelina Vorrsjö; Philippa Talmud; Aivar Lookene; Gunilla Olivecrona
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

2.  ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.

Authors:  Philip L S M Gordts; Ryan Nock; Ni-Huiping Son; Bastian Ramms; Irene Lew; Jon C Gonzales; Bryan E Thacker; Debapriya Basu; Richard G Lee; Adam E Mullick; Mark J Graham; Ira J Goldberg; Rosanne M Crooke; Joseph L Witztum; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2016-07-11       Impact factor: 14.808

Review 3.  The role of the endothelium in myocardial lipoprotein dynamics.

Authors:  A Cryer
Journal:  Mol Cell Biochem       Date:  1989 Jun 27-Jul 24       Impact factor: 3.396

Review 4.  The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk.

Authors:  Chao-Qiang Lai; Laurence D Parnell; Jose M Ordovas
Journal:  Curr Opin Lipidol       Date:  2005-04       Impact factor: 4.776

5.  GPIHBP1 missense mutations often cause multimerization of GPIHBP1 and thereby prevent lipoprotein lipase binding.

Authors:  Anne P Beigneux; Loren G Fong; André Bensadoun; Brandon S J Davies; Monika Oberer; Henrik Gårdsvoll; Michael Ploug; Stephen G Young
Journal:  Circ Res       Date:  2014-11-11       Impact factor: 17.367

6.  Characterization of recombinant wild type and site-directed mutations of apolipoprotein C-III: lipid binding, displacement of ApoE, and inhibition of lipoprotein lipase.

Authors:  H Liu; P J Talmud; L Lins; R Brasseur; G Olivecrona; F Peelman; J Vandekerckhove; M Rosseneu; C Labeur
Journal:  Biochemistry       Date:  2000-08-08       Impact factor: 3.162

7.  Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice.

Authors:  Y Ito; N Azrolan; A O'Connell; A Walsh; J L Breslow
Journal:  Science       Date:  1990-08-17       Impact factor: 47.728

8.  Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.

Authors:  C S Wang; W J McConathy; H U Kloer; P Alaupovic
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

9.  The GPIHBP1-LPL complex is responsible for the margination of triglyceride-rich lipoproteins in capillaries.

Authors:  Chris N Goulbourne; Peter Gin; Angelica Tatar; Chika Nobumori; Andreas Hoenger; Haibo Jiang; Chris R M Grovenor; Oludotun Adeyo; Jeffrey D Esko; Ira J Goldberg; Karen Reue; Peter Tontonoz; André Bensadoun; Anne P Beigneux; Stephen G Young; Loren G Fong
Journal:  Cell Metab       Date:  2014-04-10       Impact factor: 27.287

10.  Highly conserved cysteines within the Ly6 domain of GPIHBP1 are crucial for the binding of lipoprotein lipase.

Authors:  Anne P Beigneux; Peter Gin; Brandon S J Davies; Michael M Weinstein; André Bensadoun; Loren G Fong; Stephen G Young
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

View more
  19 in total

1.  Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes.

Authors:  Jenny E Kanter; Baohai Shao; Farah Kramer; Shelley Barnhart; Masami Shimizu-Albergine; Tomas Vaisar; Mark J Graham; Rosanne M Crooke; Clarence R Manuel; Rebecca A Haeusler; Daniel Mar; Karol Bomsztyk; John E Hokanson; Gregory L Kinney; Janet K Snell-Bergeon; Jay W Heinecke; Karin E Bornfeldt
Journal:  J Clin Invest       Date:  2019-07-11       Impact factor: 14.808

Review 2.  The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis.

Authors:  Philip L S M Gordts; Jeffrey D Esko
Journal:  Matrix Biol       Date:  2018-05-24       Impact factor: 11.583

3.  Impaired thermogenesis and sharp increases in plasma triglyceride levels in GPIHBP1-deficient mice during cold exposure.

Authors:  Mikael Larsson; Christopher M Allan; Patrick J Heizer; Yiping Tu; Norma P Sandoval; Rachel S Jung; Rosemary L Walzem; Anne P Beigneux; Stephen G Young; Loren G Fong
Journal:  J Lipid Res       Date:  2018-02-15       Impact factor: 5.922

4.  LncRNA HDAC11-AS1 Suppresses Atherosclerosis by Inhibiting HDAC11-Mediated Adropin Histone Deacetylation.

Authors:  Liang Li; Wei Xie
Journal:  J Cardiovasc Transl Res       Date:  2022-05-03       Impact factor: 4.132

5.  Efficacy and safety of the apolipoprotein C-III inhibitor Volanesorsen: a systematic evaluation and meta-analysis.

Authors:  Yonglang Cheng; Tongxi Li; Peng Tan; Yichao Du; Zhiwei Huang; Hao Shi; Tianying Cai; Yifan Chen; Wenguang Fu
Journal:  Endocrine       Date:  2022-03-17       Impact factor: 3.633

6.  CREBH normalizes dyslipidemia and halts atherosclerosis in diabetes by decreasing circulating remnant lipoproteins.

Authors:  Masami Shimizu-Albergine; Debapriya Basu; Jenny E Kanter; Farah Kramer; Vishal Kothari; Shelley Barnhart; Carissa Thornock; Adam E Mullick; Noemie Clouet-Foraison; Tomas Vaisar; Jay W Heinecke; Robert A Hegele; Ira J Goldberg; Karin E Bornfeldt
Journal:  J Clin Invest       Date:  2021-11-15       Impact factor: 14.808

Review 7.  Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction.

Authors:  Aleesha Shaik; Robert S Rosenson
Journal:  Cardiovasc Drugs Ther       Date:  2021-03-12       Impact factor: 3.727

8.  Association of apolipoprotein C3 with insulin resistance and coronary artery calcium in patients with type 1 diabetes.

Authors:  Teresa Buckner; Baohai Shao; Robert H Eckel; Jay W Heinecke; Karin E Bornfeldt; Janet Snell-Bergeon
Journal:  J Clin Lipidol       Date:  2020-10-31       Impact factor: 5.365

Review 9.  Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2.

Authors:  Erin E Mulvihill
Journal:  Curr Opin Lipidol       Date:  2018-04       Impact factor: 4.776

10.  Hepatitis B virus inhibits the in vivo and in vitro synthesis and secretion of apolipoprotein C3.

Authors:  Chengliang Zhu; Hengcheng Zhu; Hui Song; Limin Xu; Longxuan Li; Fang Liu; Xinghui Liu
Journal:  Lipids Health Dis       Date:  2017-11-13       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.